BI 685509, Placebo matching BI 685509 PRD9566383, Placebo matching BI 685509 PRD9566375, BI 685509, BI 685509, Placebo matching BI 685509 PRD9566374
1366-0055
Phase 2 small_molecule active
Quick answer
BI 685509, Placebo matching BI 685509 PRD9566383, Placebo matching BI 685509 PRD9566375, BI 685509, BI 685509, Placebo matching BI 685509 PRD9566374 for clinically significant portal hypertension (CSPH) in decompensated cirrhosis due to non-cholestatic liver disease is a Phase 2 program (small_molecule) at Boehringer Ingelheim International GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim International GmbH
- Indication
- clinically significant portal hypertension (CSPH) in decompensated cirrhosis due to non-cholestatic liver disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active